Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | KDM2B | Q8NHM5 | 3/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24494860 | 1.00 | SIGMAR1 (0.36) | SIGMAR1DPP4ALDH1A1OPRM1OPRL1 | |
| SCHEMBL14519149 | 0.98 | ALDH1A1 (0.36) | SIGMAR1DPP4ALDH1A1OPRM1OPRL1 | |
| SCHEMBL20757013 | 0.94 | ALDH1A1 (0.36) | ALDH1A1OPRM1OPRL1OPRK1KDM2B | |
| SCHEMBL14519158 | 0.94 | MEN1 (0.38) | SIGMAR1DPP4ALDH1A1OPRM1OPRL1 | |
| SCHEMBL20756943 | 0.92 | MEN1 (0.37) | SIGMAR1DPP4ALDH1A1OPRM1OPRL1 | |
| SCHEMBL20858038 | 0.92 | ALDH1A1 (0.37) | ALDH1A1OPRM1OPRL1OPRK1MEN1 | |
| SCHEMBL25489283 | 0.90 | OPRM1 (0.39) | ALDH1A1OPRM1OPRL1OPRK1MEN1 | |
| SCHEMBL25481370 | 0.90 | OPRL1 (0.39) | DPP4ALDH1A1OPRM1OPRL1OPRK1 | |
| SCHEMBL27290705 | 0.90 | DPP4 (0.44) | SIGMAR1DPP4OPRM1OPRL1OPRK1 | |
| SCHEMBL26796817 | 0.88 | OPRL1 (0.41) | SIGMAR1DPP4OPRM1OPRL1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | SIGMAR1 3349/4885DPP4 1075/4885ALDH1A1 1652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.